The role of PARP-2 in inhibiting prostate cancer

Bookmark and Share
Published: 27 Jul 2020
Views: 448
Prof Li Jia - Harvard Medical School, Boston, USA

Prof Li Jia speaks to ecancer about the use of PARP inhibitors in treating prostate cancer.

He talks about the paper he worked on which found that the selective targeting of PARP-2 inhibits androgen receptor signalling and prostate cancer growth. He goes on to discuss the potential of selectively targeting PARP-2 in prostate cancer, particularly in castration-resistant prostate cancer.

Prof Jia explains the differences between PARP-1 and PARP-2, how they are being studied and how that research might be used in the future.

This programme has been supported by an unrestricted educational grant from Pfizer.